A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World
← catalyst calendarSponsored by Biodesix, Inc. (industry) · BDSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
4,000estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-19 | actual | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Nodules
Primary outcomes
what the primary-completion date above is the date OFAssess Test Performance of AAT test
measured Up to 24 months
Assess Test Performance of IC test
measured 24 months
Assess serial performance of serial testing with the AAC and IC tests.
measured 24 months
Permalink · BDSX's whole pipeline · Catalyst calendar · Every registered study · What changed